Health providers and addiction experts warn the funding structure is unstable for a California initiative that steers patients with substance use disorder into long-term treatment after they are discharged from emergency rooms, which has already led some critical employees to leave their jobs.
Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and